Smith & Nephew plc (SN) Earns “Buy” Rating from Jefferies Group LLC

Smith & Nephew plc (LON:SN)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a research note issued on Thursday. They currently have a GBX 1,515 ($19.92) price target on the stock. Jefferies Group LLC’s target price would suggest a potential upside of 8.14% from the stock’s previous close.

Several other brokerages have also weighed in on SN. Citigroup Inc. restated a “sell” rating and issued a GBX 1,160 ($15.25) price objective on shares of Smith & Nephew plc in a report on Friday, October 6th. Deutsche Bank AG restated a “hold” rating and issued a GBX 1,200 ($15.78) price objective on shares of Smith & Nephew plc in a report on Friday, July 28th. Credit Suisse Group restated a “neutral” rating and issued a GBX 1,200 ($15.78) price objective on shares of Smith & Nephew plc in a report on Thursday, July 20th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a GBX 1,380 ($18.14) price objective on shares of Smith & Nephew plc in a report on Monday, September 11th. Finally, J P Morgan Chase & Co restated a “neutral” rating and issued a GBX 1,280 ($16.83) price objective on shares of Smith & Nephew plc in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company’s stock. Smith & Nephew plc currently has a consensus rating of “Hold” and an average price target of GBX 1,289.25 ($16.95).

Smith & Nephew plc (SN) opened at 1402.00 on Thursday. Smith & Nephew plc has a 12 month low of GBX 1,064.91 and a 12 month high of GBX 1,416.50. The stock has a 50 day moving average price of GBX 1,367.16 and a 200-day moving average price of GBX 1,327.10. The stock’s market cap is GBX 12.28 billion.

TRADEMARK VIOLATION NOTICE: This story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://sportsperspectives.com/2017/10/12/smith-nephew-plc-sn-earns-buy-rating-from-jefferies-group-llc.html.

In other Smith & Nephew plc news, insider Virginia Bottomley purchased 223 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were purchased at an average cost of GBX 1,380 ($18.14) per share, with a total value of £3,077.40 ($4,046.02).

Smith & Nephew plc Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew plc (LON:SN)

Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply